$CLPT
ClearPoint Neuro, Inc. Stock $clpt

$clpt Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000128555023000115 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$6.810M	$5.762M	$5.146M
YoY Change	31.62%	11.97%	12.51%
Cost Of Revenue	$2.797M	$2.489M	$1.434M
YoY Change	50.54%	73.57%	-3.5%
Gross Profit	$4.013M	$3.273M	$3.712M
YoY Change	21.02%	-11.83%	20.21%
Gross Profit Margin	58.93%	56.8%	72.13%
Selling, General & Admin	$6.067M	$2.900M	$5.054M
YoY Change	45.81%	-42.62%	18.58%
% of Gross Profit	151.18%	88.6%	136.15%
Research & Development	$2.652M	$2.429M	$2.453M
YoY Change	-26.82%	-0.98%	-6.73%
% of Gross Profit	66.09%	74.21%	66.08%
Depreciation & Amortization	$183.0K	$150.0K	$37.00K
YoY Change	815.0%	305.41%	-27.45%
% of Gross Profit	4.56%	4.58%	1.0%
Operating Expenses	$8.719M	$5.329M	$7.507M
YoY Change	12.0%	-29.01%	8.92%
Operating Profit	-$4.706M	-$4.897M	-$3.795M
YoY Change	5.3%	29.04%	-0.24%
Interest Expense	$91.00K	$100.0K	$32.00K
YoY Change	8.33%	212.5%	-113.45%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	-$12.00K	-$25.00K
YoY Change		-52.0%	-140.32%
Pretax Income	-$4.619M	-$4.810M	-$3.788M
YoY Change	5.34%	26.98%	-4.82%
Income Tax
% Of Pretax Income
Net Earnings	-$4.619M	-$4.809M	-$3.788M
YoY Change	5.34%	26.95%	-4.82%
Net Earnings / Revenue	-67.83%	-83.46%	-73.61%
Basic Earnings Per Share		-$0.20	-$0.15
Diluted Earnings Per Share	-$0.19	-$0.20	-$154.6K
COMMON SHARES
Basic Shares Outstanding	24.62M shares	24.64M shares	24.50M shares
Diluted Shares Outstanding		24.63M shares	24.50M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.14M	$24.34M	$40.46M
YoY Change	-38.28%	-39.84%	-29.82%
Cash & Equivalents	$23.14M	$24.30M	$18.71M
Short-Term Investments	$0.00	$0.00	$21.75M
Other Short-Term Assets	$1.910M	$1.560M	$1.658M
YoY Change	10.85%	-5.91%	96.91%
Inventory	$7.911M	$8.987M	$8.284M
Prepaid Expenses
Receivables	$3.211M	$2.424M	$3.411M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$36.17M	$37.31M	$53.81M
YoY Change	-29.32%	-30.67%	-17.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.953M	$1.355M	$2.495M
YoY Change	514.52%	-45.69%	-11.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$495.0K	$109.0K	$579.0K
YoY Change	277.86%	-81.17%	-4.3%
Total Long-Term Assets	$6.489M	$6.527M	$3.924M
YoY Change	50.56%	66.34%	5.85%
TOTAL ASSETS
Total Short-Term Assets	$36.17M	$37.31M	$53.81M
Total Long-Term Assets	$6.489M	$6.527M	$3.924M
Total Assets	$42.66M	$43.84M	$57.74M
YoY Change	-23.12%	-24.08%	-15.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$393.0K	$789.0K	$1.387M
YoY Change	44.49%	-43.11%	78.51%
Accrued Expenses	$4.424M	$3.630M	$3.973M
YoY Change	-18.83%	-8.63%	17.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.430M	$5.589M	$6.095M
YoY Change	9.46%	-8.3%	32.85%
LONG-TERM LIABILITIES
Long-Term Debt	$9.949M	$9.940M	$9.879M
YoY Change	0.57%	0.62%	-43.91%
Other Long-Term Liabilities	$4.109M	$4.220M	$1.886M
YoY Change	113.79%	123.75%	-20.79%
Total Long-Term Liabilities	$14.06M	$14.16M	$11.77M
YoY Change	18.98%	20.36%	-41.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.430M	$5.589M	$6.095M
Total Long-Term Liabilities	$14.06M	$14.16M	$11.77M
Total Liabilities	$21.49M	$19.74M	$17.86M
YoY Change	15.51%	10.54%	-27.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$172.0M	-$167.8M
YoY Change	14.67%
Common Stock	$193.6M	$191.9M
YoY Change	3.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.17M	$24.09M	$39.88M
YoY Change
Total Liabilities & Shareholders Equity	$42.66M	$43.84M	$57.74M
YoY Change	-23.12%	-24.08%	-15.96%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$4.619M	-$4.809M	-$3.788M
YoY Change	5.34%	26.95%	-4.82%
Depreciation, Depletion And Amortization	$183.0K	$150.0K	$37.00K
YoY Change	815.0%	305.41%	-27.45%
Cash From Operating Activities	-$1.169M	-$1.790M	-$3.852M
YoY Change	-61.86%	-53.53%	16.87%
INVESTING ACTIVITIES
Capital Expenditures	$188.0K	$230.0K	-$631.0K
YoY Change	-25.98%	-136.45%	404.8%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$188.0K	-$230.0K	-$631.0K
YoY Change	-101.6%	-63.55%	404.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.000K
YoY Change			-92.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	155.0K	-90.00K	-329.0K
YoY Change	-30.18%	-72.64%	-27.21%
NET CHANGE
Cash From Operating Activities	-1.169M	-1.790M	-3.852M
Cash From Investing Activities	-188.0K	-230.0K	-631.0K
Cash From Financing Activities	155.0K	-90.00K	-329.0K
Net Change In Cash	-1.202M	-2.110M	-4.812M
YoY Change	-113.5%	-56.15%	24.24%
FREE CASH FLOW
Cash From Operating Activities	-$1.169M	-$1.790M	-$3.852M
Capital Expenditures	$188.0K	$230.0K	-$631.0K
Free Cash Flow	-$1.357M	-$2.020M	-$3.221M
YoY Change	-59.11%	-37.29%	1.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9874000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2424000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2665000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	8987000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9303000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1557000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1723000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	37310000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	51180000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1355000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	806000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3689000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1895000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	405000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	450000	usd
CY2023Q3	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	969000	usd
CY2022Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	1028000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	109000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	131000	usd
CY2023Q3	us-gaap	Assets Assets	43837000	usd
CY2022Q4	us-gaap	Assets Assets	55490000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	789000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	272000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2288000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2824000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	953000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32580000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1645000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	77000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	314000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-7052000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	27410000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	899000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2954000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2065000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	384000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	561000	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1175000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1066000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24630181	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24630181	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1307000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1584000	usd
CY2023Q3	clpt	Option Exercises Cash And Cashless Shares OptionExercisesCashAndCashlessShares	14312	shares
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	91000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24094000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	usd
CY2022Q1	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	3000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24342000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45730000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	880000	usd
CY2022Q2	clpt	Warrant Exercises Cash And Cashless WarrantExercisesCashAndCashless	253000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	260000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4303000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42820000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1175000	usd
CY2022Q3	clpt	Option Exercises Cash And Cashless Shares OptionExercisesCashAndCashlessShares	23763	shares
CY2022Q3	clpt	Option Exercises Cash And Cashless OptionExercisesCashAndCashless	7000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	336000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3788000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	39878000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12050000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	903000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-92000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	443000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	224000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4536000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2954000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	42000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	41000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	590000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	400000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	126000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	159000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	662000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	982000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-263000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3318000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-241000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1150000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-22000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-31000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1023000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1255000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-553000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-400000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	243000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	144000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12551000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13102000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	696000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	214000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	167000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	678000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21590000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	10000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9137000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22482000	usd
	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	0	usd
	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	263000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	173000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	336000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	314000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	260000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	187000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3273000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35397000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27615000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54109000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18712000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	554000	usd
	us-gaap	Interest Paid Net InterestPaidNet	351000	usd
CY2023Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2500000	usd
CY2023Q3	clpt	Number Of Customers NumberOfCustomers	50	customer
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2022 audited consolidated financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with SEC rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with GAAP. The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2022 Form 10-K. The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for a complete set of financial statements. The results of operations for the three and nine months ended September 30, 2023, may not be indicative of the results to be expected for the entire year or any future periods.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. The Company classifies the U.S. government debt securities as held-to-maturity in accordance with ASC 320, "Investments - Debt and Equity Securities." Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity and are recorded at amortized cost on the accompanying condensed consolidated balance sheet, adjusted for the accretion of discounts using the effective interest method.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At September 30, 2023, the Company had approximately $1.5 million in bank balances that were in excess of the insured limits. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, there were two customers whose accounts receivable balances represented 29% and 24% of accounts receivable at that date. At December 31, 2022, one customer accounted for 19% of accounts receivable at that date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pharmaceutical customer, a related party who is a stockholder, a noteholder, and whose chief executive officer is a representative on the Company's Board of Directors (see Note 6), for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 12% and 14% of total sales in the three-month periods ended September 30, 2023 and 2022, respectively, and 12% and 16% of total sales in the nine-month periods ended September 30, 2023 and 2022, respectively. There was one additional customer who comprised 10% of the total sales in the three-month period ended September 30, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit to a customer, the Company generally performs credit evaluations of the customers’ financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at September 30, 2023, and December 31, 2022, was $1.0 million and $0.1 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; dependence on third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1500000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2023 classifies share-based compensation in the same income statement line items as the cash compensation paid to recipient employees, rather than in general and administrative expense, as had been the practice in previous years. The accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2022 have been conformed to the 2023 presentation.</span></div>
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5762000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5146000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17145000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15377000	usd
CY2023Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	600000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	300000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	500000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24300000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27600000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9900000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1584000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1175000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4536000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1584000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1175000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4536000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2954000	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6928000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6513000	usd
CY2023Q3	clpt	Inventory Software Licenses InventorySoftwareLicenses	211000	usd
CY2022Q4	clpt	Inventory Software Licenses InventorySoftwareLicenses	210000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1848000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2580000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	8987000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9303000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	405000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	450000	usd
CY2023Q3	clpt	Inventory Net Including Noncurrent InventoryNetIncludingNoncurrent	9392000	usd
CY2022Q4	clpt	Inventory Net Including Noncurrent InventoryNetIncludingNoncurrent	9753000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10000000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	65000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	9935000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	200000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	100000	usd
	us-gaap	Lease Cost LeaseCost	500000	usd
	us-gaap	Lease Cost LeaseCost	400000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1398286	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.69
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	111107	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.10
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	4374	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	41.52
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1485019	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M8D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1867000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1258707	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1867000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1485019	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y8M8D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1867000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
clpt-20230930_cal.xml	Edgar Link	unprocessable
0001285550-23-000115-index-headers.html	Edgar Link	pending
0001285550-23-000115-index.html	Edgar Link	pending
0001285550-23-000115.txt	Edgar Link	pending
0001285550-23-000115-xbrl.zip	Edgar Link	pending
clpt-20230930.htm	Edgar Link	pending
clpt-20230930.xsd	Edgar Link	pending
clpt-20230930xex311.htm	Edgar Link	pending
clpt-20230930xex312.htm	Edgar Link	pending
clpt-20230930xex32.htm	Edgar Link	pending
clpt-20230930_def.xml	Edgar Link	unprocessable
clpt-20230930_lab.xml	Edgar Link	unprocessable
clpt-20230930_pre.xml	Edgar Link	unprocessable
clpt-20230930_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLPT
ClearPoint Neuro, Inc. Stock $clpt

2023 Q4 Form 10-Q Financial Statement

#000128555023000115 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT ClearPoint Neuro, Inc. Stock $clpt

2023 Q4 Form 10-Q Financial Statement

#000128555023000115 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT
ClearPoint Neuro, Inc. Stock $clpt